Lb Pharmaceuticals (LBRX) Operating Leases (2024 - 2026)

Lb Pharmaceuticals has reported Operating Leases for 3 years, with the latest figure at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases changed N/A year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (changed N/A YoY), and the FY2025 full-year result was $2.8 million, down 11.72% from the prior year.
• Operating Leases for Q1 2026 stood at $2.7 million, down from $2.8 million in the prior quarter.
• The five-year high for Operating Leases was $3.2 million in Q4 2024, with the low at $2.7 million in Q1 2026.
• Average Operating Leases over 3 years is $2.9 million, with a median of $2.9 million recorded in 2025.
• Peak annual rise in Operating Leases reached 11.72% in 2025, while the deepest fall reached 11.72% in 2025.
• Tracing LBRX's Operating Leases over 3 years: stood at $3.2 million in 2024, then retreated by 11.72% to $2.8 million in 2025, then retreated by 3.49% to $2.7 million in 2026.
• The last three Operating Leases figures came in at $2.7 million (Q1 2026), $2.8 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.

Peer Comparison